首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice
【24h】

Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice

机译:蛋白质和改性痘苗病毒Ankara的流感病毒核蛋白疫苗在Balb / c小鼠中是差异的免疫原性

获取原文
获取原文并翻译 | 示例
           

摘要

Because of the high variability of seasonal influenza viruses and the eminent threat of influenza viruses with pandemic potential, there is great interest in the development of vaccines that induce broadly protective immunity. Most probably, broadly protective influenza vaccines are based on conserved proteins, such as nucleoprotein (NP). NP is a vaccine target of interest as it has been shown to induce cross-reactive antibody and T cell responses. Here we tested and compared various NP-based vaccine preparations for their capacity to induce humoral and cellular immune responses to influenza virus NP. The immunogenicity of protein-based vaccine preparations with Matrix-M adjuvant as well as recombinant viral vaccine vector modified Vaccinia virus Ankara (MVA) expressing the influenza virus NP gene, with or without modifications that aim at optimization of CD8(+) T cell responses, was addressed in BALB/c mice. Addition of Matrix-M adjuvant to NP wild-type protein-based vaccines significantly improved T cell responses. Furthermore, recombinant MVA expressing the influenza virus NP induced strong antibody and CD8(+) T cell responses, which could not be improved further by modifications of NP to increase antigen processing and presentation.
机译:由于季节性流感病毒的高度变化和流感病毒具有大流行潜力的突出威胁,因此对疫苗的发育非常兴趣,促使巨大保护免疫力。大多数可能,广泛保护的流感疫苗基于保守的蛋白质,例如核蛋白(NP)。 NP是感兴趣的疫苗靶标,因为已经显示出诱导交叉反应抗体和T细胞应答。在这里,我们测试并比较了各种基于NP的疫苗制剂,以诱导对流感病毒NP的体液和细胞免疫应答的能力。蛋白质疫苗制剂的免疫原性与基质-M辅助剂以及表达流感病毒NP基因的重组病毒疫苗载体改性痘苗病毒ankara(MVA),有或没有修饰的旨在优化CD8(+)T细胞反应,在Balb / C小鼠中解决。向NP野生型蛋白质的疫苗添加基质-M佐剂显着改善了T细胞应答。此外,表达流感病毒NP诱导的强抗体和CD8(+)T细胞反应的重组MVA,通过NP的修饰不能进一步改善,以增加抗原加工和呈现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号